Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer

HPB

Volumn 12, Issue 1, 2010, Pages 73-79

  McClaine, Rebecca J ^a   Lowy, Andrew M ^a   Sussman, Jeffrey J ^a   Schmulewitz, Nathan ^a   Grisell, David L ^a   Ahmad, Syed A ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Borderline resectable; Neoadjuvant therapy; Pancreatic cancer

Indexed keywords

CISPLATIN; ERLOTINIB; GEMCITABINE; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELIAC ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATIC ARTERY; HUMAN; MALE; MESENTERIC ARTERY; PANCREAS CANCER; PORTAL VEIN;

EID: 75449086813     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2009.00136.x     Document Type: Article

References (8)

1. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H et al. (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13:1035-1046.
2. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH et al. (2007) Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246:52-60.
3. National Comprehensive Cancer Network (NCCN). (2007) Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. v.1.2008. http:// www.nccn.org/professionals/physician-gls/default.asp. [Accessed 1 February 2009].
4. Katz MHG, Pisters PWT, Evans DB, Sun CC, Lee JE, Fleming JB et al. (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206:833-848.
5. Ahmad SA, Lowy AM, McIntyre BC, Matthews JB. (2005) Pancreaticoduodenectomy. J Gastrointest Surg 9:138-143.
6. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J et al. (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138:8-13.
7. Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ et al. (2007) The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 140:31-35.
8. Neoptolemos JP, Stocken DD, Friess H, Bass C, Dunn JA, Hickey H et al., for the European Study Group for Pancreatic Cancer. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200-1210.